Abstract
Breast cancer is conventionally treated by surgery, chemotherapy and radiation therapy followed by post operational hormonal therapy. Tamoxifen citrate is a best option to treat breast cancer because its selective estrogen receptor modulation activity. Owing to its antiestrogenic action on breast as well as uterine cells, Tamoxifen citrate shows uterine toxicity. The dose 20 mg per day of Tamoxifen citrate required to show therapeutic effect causes side effects and toxicity to vital organs such as liver, kidney and uterus. In the present study, transferrin-conjugated solid lipid nanoparticles (SLNs) were successfully prepared to enhance the active targeting of tamoxifen citrate in breast cancer. Developed formulations were evaluated for particle size, surface charge, surface morphology and in vitro dissolution studies. Developed formulations exhibited more cytotoxicity as compared to pure Tamoxifen citrate solution in time as well as concentration dependent manner on human breast cancer MCF-7 cells. Further, cell uptake and flow cytometry studies confirmed the qualitative uptake of developed D-SLN and SMD-SLN by human breast cancer MCF-7 cells. Overall, proposed study highlights that transferrin engineered nanocarriers could enhance the therapeutic response of nanomedicines for breast cancer treatment.
Highlights
A day’s advancement and expenditure in cancer research is growing year by year because changing lifestyle and many other factors causing serious life-threatening cancer
The maximum mortality is claimed in Estrogen Receptor Positive (ER+) breast cancer where the risk factors involved are related to age and estrogen exposure (Osborne, 1998)
The goal of this study is to combine the advantages of the drug Tamoxifen citrate and colloidal nanocarriers system viz. solid lipid nanoparticles (SLNs) to target the cancer cells and protect the normal cells
Summary
A day’s advancement and expenditure in cancer research is growing year by year because changing lifestyle and many other factors causing serious life-threatening cancer. Breast cancer is most occurred cancer in women as compared to other different types of cancers, currently breast cancer is most focused area of interest for research (Devi et al, 2020). As per WHO report breast cancer has second highest reported cases incident among all cancer cases. In US one among eight women will be patient of Targeted SLNs for Breast Cancer breast cancer in course of her life period. Fatality rate of breast cancer is high to US women as compare to other cancer, beside lung cancer (Tagde et al, 2020). The maximum mortality is claimed in Estrogen Receptor Positive (ER+) breast cancer where the risk factors involved are related to age and estrogen exposure (Osborne, 1998)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
